培非格司亭生物类似药（Biocon）(Pegfilgrastim-Jmdb) - 药物靶点：CSF-3R_在研适应症：中性粒细胞减少，粒细胞减少性发热，化疗引起的发热性中性粒细胞减少症_专利_临床

To compare the Pharmacokinetics (PK) / Pharmacodynamics(PD)of a single subcutaneous (sc) injection (3.6 mg) of MYL-1401H and G-Lasta in Japanese healthy adult volunteers

开始日期2022-03-17

申办/合作机构-

NCT05573386

/ Unknown statusN/AIIT

A Single Center, Prospective Study to Compare the Quality and Quantity of the Cellular Content of M-PRP Harvested After Peripheral Mobilization of Progenitor Cells Using Filgrastim Versus Pegfilgrastim

The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and pegfilgrastim. The main question it aims to answer is:
• Will participants have a similar cellular content when comparing a 4-day filgrastim treatment to a one-day pegfilgrastim treatment?
Participants will have the following intervention administered:
* 130mL of blood will be drawn on the first visit after consent and in followup visits after administering treatment (4 days for filgrastim, 7 days for pegfilgrastim)
* Half of all participants will receive filgrastim first, followed by pegfilgrastim 8 weeks after filgrastim treatment concludes. The other half will receive the treatments in reverse order
Researchers will compare the quality and quantity of cell content after each treatment administration as well as comparing differences in data dependent on which order treatment was given.

开始日期2021-08-09

申办/合作机构

Andrews Research & Education Foundation, Inc.

IRCT20180119038433N3

/ Suspended临床3期IIT

Comparison of the effect of pegfilgrastim with filgrastim on the neutrophil count of cancer patients under chemotherapy, a randomization clinical trial.

开始日期2020-10-22

申办/合作机构

Semnan University

100 项与培非格司亭生物类似药（Biocon）相关的临床结果

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的转化医学

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的专利（医药）

登录后查看更多信息

21

项与培非格司亭生物类似药（Biocon）相关的文献（医药）

2024-04-09·Blood advances

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen

Article

作者: Petrich, Adam ; Gordon, Leo ; Nelson, Valerie ; Helenowski, Irene ; Ma, Shuo ; Pro, Barbara ; Klein, Andreas ; Winter, Jane ; Shah, Nirav N. ; Mi, Xinlei ; Fenske, Timothy S. ; Chen, Ruohui ; Evens, Andrew M. ; Galvez, Carlos ; Karmali, Reem ; Hamadani, Mehdi ; Jagadeesh, Deepa

Abstract:

MYC-aberrant non-Hodgkin lymphoma (NHL) is associated with poor outcomes with conventional chemotherapy. Ixazomib is an orally bioavailable proteasome inhibitor that targets drivers of MYC expression and has demonstrated preclinical activity in aggressive MYC-aberrant NHL. We conducted a phase 1/2 study evaluating the safety and efficacy of DA-EPOCH-R with adjunctive ixazomib in aggressive MYC-aberrant NHL. For induction, patients received 6 cycles of DA-EPOCH-R with ixazomib administered twice per 21-day cycle; responders continued weekly ixazomib maintenance for up to 1 year. Primary objectives were to determine the maximum tolerated dose in phase 1 and efficacy of DA-EPOCH-R with ixazomib as measured by 12-month progression-free survival (PFS) rate in phase 2. Thirty-six patients were evaluable for response. Median age was 63 years (range, 31-77) and 44% had double-hit lymphoma (DHL)/triple-hit lymphoma (THL). In phase 1, 3 mg of ixazomib was established as recommended phase 2 dose. Twenty-nine (76.3%) patients completed 6 cycles of DA-EPOCH-R and 25 (65.8%) underwent dose escalations. The ORR after induction was 97% (95% confidence interval, 81-100) with a CR rate of 69%. At median follow-up of 18.8 months, the 12-month PFS and overall survival (OS) rates were 78% and 86%, respectively. For DHL/THL vs dual expressor lymphomas (DEL), 12-month PFS rates were 53% vs 95% and 12-month OS rates were 65% vs 100%, respectively. Grade ≥3 toxicities were predominantly hematologic. Twenty-seven (75%) of patients experienced neuropathy, nearly all low-grade. DA-EPOCH-R induction with adjunctive ixazomib is feasible and appears effective in patients with DEL. This trial was registered at www.clinicaltrials.gov as #NCT02481310.

2023-08-01·Clinical pharmacology in drug development

Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor

Article

作者: Ishizawa, Keisuke ; Ishida, Tatsuhiro ; Taro, Shimizu ; Nakamura, Shingen ; Okada, Naoto ; Ando, Hidenori ; Goda, Mitsuhiro ; Kitahara, Takashi ; Abe, Masahiro

Abstract:

Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half‐life and efficacy. We previously reported that the PEGylated granulocyte colony‐stimulating factor (PEG‐G‐CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti‐PEG antibody titers and the clinical impact of PEG‐G‐CSF in 19 hematological patients. A gradual decrease of anti‐PEG antibody titers from baseline was observed after PEG‐G‐CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG‐G‐CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut‐off values of pretreated anti‐PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti‐PEG antibody titers above this cut‐off value (P = .033). An enzyme‐linked immunosorbent assay revealed that some anti‐PEG antibodies in patients with anti‐PEG antibody titers above the cut‐off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti‐PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti‐PEG antibodies and the development of adverse events after PEG‐G‐CSF administration.

2023-03-01·Journal of the National Comprehensive Cancer Network : JNCCN

Primary Mediastinal B-Cell Lymphoma in Children and Young Adults

Review

作者: Chadburn, Amy ; Forlenza, Christopher J ; Giulino-Roth, Lisa

Primary mediastinal B-cell lymphoma (PMBCL) is a rare but aggressive mature B-cell lymphoma that arises from thymic B cells and most commonly affects adolescents and young adults. PMBCL is now recognized by the WHO as a distinct entity from diffuse large B-cell lymphoma (DLBCL), not otherwise specified, with a unique clinical presentation and distinct morphologic features and molecular alterations. Similar to classic Hodgkin lymphoma, PMBCL tumors are characterized by alterations in the nuclear factor-κB and JAK/STAT pathways. These tumors also exhibit an immune evasion phenotype marked by upregulation of PD-L1 and loss of B2M. Historic data indicates that outcomes for pediatric patients with PMBCL are inferior compared with pediatric patients with DLBCL treated on the same protocols, and there is no current standard approach to initial treatment. Common regimens used for children with PMBCL include multiagent chemotherapy regimens designed for Burkitt lymphoma, such as Lymphomes Malins B (LMB)-based or Berlin-Frankfurt-Münster (BFM)-based chemotherapy ± rituximab. Based on initial data in adults showing excellent outcomes with the use of DA-EPOCH-R regimens, these regimens have also been adopted in pediatrics, although with mixed results. Novel agents are currently being studied in PMBCL with the goal of improving outcomes and reducing reliance on radiation and/or high-dose chemotherapy. Immune checkpoint blockade with PD-1 inhibition is of particular interest given the upregulation of PD-L1 in PMBCL and the known efficacy of these agents in the relapsed setting. Future efforts in PMBCL will also seek to determine the role of FDG-PET in evaluating response to therapy and the role of biomarkers in risk stratification.

29

项与培非格司亭生物类似药（Biocon）相关的新闻（医药）

2025-04-11

·Pharmaceutical Technology

FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer

The data showed no clinically meaningful differences between the biosimilar and the reference product in terms of safety, efficacy, immunogenicity and pharmacokinetics. Credit: Gorodenkoff/Shutterstock. Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne (bevacizumab-nwgd), a biosimilar to the reference Avastin (bevacizumab). Jobevne is a recombinant humanised monoclonal antibody which functions as a vascular endothelial growth factor inhibitor, targeting the cancer and restricting the supply of blood to tumours. The approval bolsters the company’s biosimilar oncology portfolio in the US, which includes Fulphila (Pegfilgrastim-jmdb) and Ogivri (Trastuzumab-dkst). The company has been marketing bevacizumab under the name Abevmy in Europe, where it was approved in February 2021. It also gained approval in November of the same year in Canada. The FDA approval was supported by a comprehensive package comprising comparative pharmacokinetic, efficacy, nonclinical, functional, safety, analytical and structural data that demonstrated Jobevne’s high similarity to the reference product. In safety, efficacy, immunogenicity and pharmacokinetics, the data showed no clinically meaningful differences between Jobevne and Avastin. Biocon Biologics CEO and managing director Shreehas Tambe stated: “The US FDA approval of Jobevne (bevacizumab-nwgd) is a significant milestone — our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio. “It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” Biocon Biologics has commercialised nine biosimilars from a pipeline of 20 products in the US, Australia, Canada, Japan and Europe. Its development pipeline of biosimilar assets spans oncology, ophthalmology, immunology, diabetology and other non-communicable conditions. In August 2024, the company reached a settlement and licence agreement with Janssen Biotech, Janssen Sciences Ireland and Johnson & Johnson (together called Janssen) for the commercialisation of Bmab 1200 (bUstekinumab), a proposed biosimilar to Stelara.

上市批准引进/卖出免疫疗法

2025-04-10

·PipelineReview

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 10, 2025 I Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin® (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor. The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. , said: “The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” In the U.S., sales of bevacizumab were approximately $2.0 billion in 2023.** Biocon Biologics is a leading global player in biosimilars and insulin production and has achieved many “firsts” in the industry including the first to receive approval of a trastuzumab in the United States, OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Serving over 5 million patients annually, Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including seven approved biosimilars in the United States and six in Canada, with a robust development pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas. About JOBEVNE: The approval for JOBEVNE (bevacizumab-nwgd) was based on a comprehensive package of comparative pharmacokinetic, safety, efficacy, nonclinical, structural, analytical and functional data, which confirmed that JOBEVNE is highly similar to Avastin® (bevacizumab). The data demonstrated that there were no clinically meaningful differences between JOBEVNE and Avastin® in terms of pharmacokinetics, safety, efficacy, and immunogenicity. INDICATIONS AND USAGE: JOBEVNE is a vascular endothelial growth factor inhibitor indicated for the treatment of: * Limitations of Use: JOBEVNE is not indicated for adjuvant treatment of colon cancer. JOBEVNE is a trademark of Biosimilars Newco Limited, a Biocon Biologics Company. OGIVRI, FULPHILA, SEMGLEE and ABEVMY are registered trademarks of Biosimilars Newco Limited, a Biocon Biologics Company. BIOCON BIOLOGICS and the Biocon Biologics Logo are registered trademarks of Biocon Biologics Limited. All other trademarks are the property of their respective owners. **Sales projections are based on Biocon Biologics’ analysis of IQVIA 2023 data. About Biocon Biologics Limited: Biocon Biologics Ltd. (BBL) , a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized nine biosimilars from its pipeline of 20 products in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It’s pipeline has several biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website www.bioconbiologics.com ; Follow us on X (formerly Twitter ): @BioconBiologics and LinkedIn : Biocon Biologics for company updates. Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com ; Follow-us on X (formerly Twitter ) @bioconlimited and LinkedIn : Biocon for company updates. SOURCE: Biocon Biologics

上市批准免疫疗法

2025-04-09

·Pharmaindustrial

Biocon Biologics Announces USFDA Approval of JOBEVNE Biosimilar for Cancer Treatment

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd announced that the US Food and Drug Administration (US FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin® (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor. The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said: "The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients." In the U.S., sales of bevacizumab were approximately USD 2.0 billion in 2023.

上市批准免疫疗法生物类似药

100 项与培非格司亭生物类似药（Biocon）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AA13	DB00019

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
中性粒细胞减少	欧盟	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	冰岛	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	列支敦士登	Biocon Biologics Ireland Ltd.	2018-11-20
中性粒细胞减少	挪威	Biocon Biologics Ireland Ltd.	2018-11-20
粒细胞减少性发热	澳大利亚	Alphapharm Pty Ltd.	2018-08-17
化疗引起的发热性中性粒细胞减少症	美国	Mylan Pharmaceuticals, Inc.	2018-06-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	保加利亚	Mylan NV	2015-03-01
乳腺癌	临床3期	保加利亚	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	格鲁吉亚	Mylan NV	2015-03-01
乳腺癌	临床3期	格鲁吉亚	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	德国	Mylan NV	2015-03-01
乳腺癌	临床3期	德国	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	匈牙利	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	匈牙利	Mylan NV	2015-03-01
乳腺癌	临床3期	波兰	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	波兰	Mylan NV	2015-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO_GI2023	临床2期	食管癌新辅助	67	Day 3 PG-containing DCF	簾鹹範鏇獵壓鏇觸觸鬱(衊繭艱鏇齋鏇衊積顧餘) = 膚顧醖獵餘窪製積艱鏇憲齋遞願糧廠製窪鏇膚 (憲遞廠糧糧築鏇獵餘壓 ) 更多	-	2023-01-24
				No PG DCF	簾鹹範鏇獵壓鏇觸觸鬱(衊繭艱鏇齋鏇衊積顧餘) = 糧簾構夢艱蓋網廠艱觸憲齋遞願糧廠製窪鏇膚 (憲遞廠糧糧築鏇獵餘壓 ) 更多
ESMO_ASIA2022	N/A	侵袭性非霍奇金淋巴瘤	263	PEG G-CSF	窪淵廠鹽衊簾膚壓蓋窪(夢襯觸築顧襯窪製觸鑰) = 顧夢鑰簾醖鑰壓窪壓顧壓選憲鏇衊憲鬱鏇窪鑰 (願鏇廠鬱築蓋網淵鏇廠 ) 更多	-	2022-12-03
				Non-PEG G-CSF	窪淵廠鹽衊簾膚壓蓋窪(夢襯觸築顧襯窪製觸鑰) = 範遞夢夢遞網淵壓壓膚壓選憲鏇衊憲鬱鏇窪鑰 (願鏇廠鬱築蓋網淵鏇廠 ) 更多
ASCO_GI2022	N/A	食管癌新辅助	52	DCF with prophylactic pegfilgrastim (D3PG)	鬱繭廠構淵淵壓鏇鑰壓(夢繭壓觸衊簾廠齋鑰鹽) = 夢襯醖鏇鹹糧鬱構遞鹹艱糧鏇願壓範鬱衊廠製 (窪築鑰觸選製範鹹鑰鏇 ) 更多	积极	2022-01-19
				Standard DCF (NPG)	鬱繭廠構淵淵壓鏇鑰壓(夢繭壓觸衊簾廠齋鑰鹽) = 範餘範憲壓顧顧範鹹鹹艱糧鏇願壓範鬱衊廠製 (窪築鑰觸選製範鹹鑰鏇 ) 更多
ASCO2021	N/A	慢性淋巴细胞白血病 \| 淋巴瘤	116	Pegfilgrastim (PFG)	獵觸築夢醖壓顧鏇糧壓(鑰顧築網網遞繭壓獵遞) = 壓鏇積窪繭醖顧膚製觸膚範鹹窪遞膚遞憲製膚 (顧憲範廠鏇鏇範範鹹醖 ) 更多	-	2021-05-28
				PFG-cbqv	獵觸築夢醖壓顧鏇糧壓(鑰顧築網網遞繭壓獵遞) = 繭淵憲壓膚範鑰繭繭顧膚範鹹窪遞膚遞憲製膚 (顧憲範廠鏇鏇範範鹹醖 ) 更多
ASCO2021	N/A	非霍奇金淋巴瘤	100	Pegfilgrastim	醖簾糧築鹹範鑰淵廠醖(網夢顧網網醖廠窪製鹹) = 鹹壓衊範窪鬱製觸淵繭艱壓夢構窪廠鹽選繭窪 (獵壓築構積膚範壓襯簾 ) 更多	积极	2021-05-28
				Pegfilgrastim-cbqv	鏇顧網積願鹽鹽夢鹽壓(繭鹹壓鬱鑰構齋醖製鹹) = 膚醖鑰構壓鑰襯憲淵鑰鹽醖選觸膚顧鬱繭壓窪 (獵壓選憲淵獵繭遞淵襯 ) 更多
ASCO2020	N/A	-	-	Pegfilgrastim	淵選壓淵遞簾鏇夢夢觸(獵範鹽顧構齋膚廠範鏇) = 獵鬱膚夢選築餘網壓網鏇遞衊蓋襯艱簾顧襯範 (築艱膚壓繭廠艱築窪夢 )	积极	2020-05-25
				Biosimilar Pegfilgrastim	膚簾鬱鹹衊艱鏇顧夢鬱(膚積遞築壓顧選積餘選) = 憲艱鹹餘網範遞鹹餘積製艱範選獵構鏇齋壓醖 (製構鹹糧繭範鹹鹽壓憲 )
ASCO_GI2020	N/A	胃肠道肿瘤	157	Same-day pegfilgrastim	鑰遞齋鏇鏇憲鬱簾夢築(遞糧鑰顧廠鹽糧積蓋範) = 積夢簾製鬱艱衊遞廠糧膚遞獵蓋襯餘醖繭襯艱 (選襯鏇繭壓蓋壓窪繭餘, 450 ~ 23800)	积极	2020-02-04
ASCO2019	N/A	转移性结直肠癌	-	Pegfilgrastim-treated	鏇蓋壓積齋衊構構遞觸(顧餘壓鹽醖鏇鏇齋憲襯) = 夢築廠願壓鑰鑰鹹鹹製糧襯繭鬱鹽憲鹽製鏇廠 (齋糧鬱網範獵夢壓膚範 ) 更多	不佳	2019-05-26
				pegfilgrastim (Peg-untreated)	鏇蓋壓積齋衊構構遞觸(顧餘壓鹽醖鏇鏇齋憲襯) = 鏇鹽齋觸範齋範淵鏇製糧襯繭鬱鹽憲鹽製鏇廠 (齋糧鬱網範獵夢壓膚範 ) 更多
ASCO2019	N/A	前列腺癌	65	As-needed filgrastim (ANF)	艱窪積繭鬱鹽構選鹽鹽(遞糧鏇醖膚繭鏇窪鬱簾) = 網選築齋壓顧鑰廠築鹹齋襯襯襯糧構糧構範襯 (膚鏇衊獵壓鬱衊網鹹廠 ) 更多	积极	2019-05-26
				Prophylactic pegfilgrastim (PPF)	艱窪積繭鬱鹽構選鹽鹽(遞糧鏇醖膚繭鏇窪鬱簾) = 顧願簾淵範鹹築醖夢夢齋襯襯襯糧構糧構範襯 (膚鏇衊獵壓鬱衊網鹹廠 ) 更多
NCT02467868 (Pubmed) 人工标引	临床3期	中性粒细胞减少	135	MYL-1401H	衊餘積窪糧壓壓淵鏇製(餘築鹹廠糧顧鹽餘艱餘) = 廠衊積廠獵選網鹹鬱願遞簾醖鏇鏇鹹膚顧鹹構 (膚壓襯構蓋窪製願獵鏇, 0.93) 更多	相似	2019-05-01
				pegfilgrastim	衊餘積窪糧壓壓淵鏇製(餘築鹹廠糧顧鹽餘艱餘) = 憲積廠蓋鑰憲遞簾鏇範遞簾醖鏇鏇鹹膚顧鹹構 (膚壓襯構蓋窪製願獵鏇, 1.10) 更多